Moderna CEO Expresses Confidence in Personalized Cancer Vaccine Expansion Beyond Melanoma
Moderna CEO Stéphane Bancel is defending the potential of the company's experimental personalized cancer vaccine, intismeran autogene. Despite recent investor skepticism following phase 3 trial results for melanoma when used in combination with Merck's Keytruda, Bancel maintains that the therapeutic platform holds significant promise for a broader range of cancer indications. The company aims to leverage its mRNA technology to expand the application of this personalized approach. While the specific melanoma data caused some market volatility, management is focusing on the long-term scalability and versatility of the vaccine across different oncology segments.
Topics: cancer vaccine clinical trials melanoma
Read the full article at Seeking Alpha
Part of the story Moderna's mRNA Pipeline Expansion Drives Growth Potential Beyond COVID-19 Vaccines (3 articles)